Загрузка...
Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials
Maraviroc blocks HIV-1 entry into CD4+ cells by interrupting the interaction between viral gp120 and cell-surface CCR5. Resistance to CCR5 antagonist–mediated inhibition can develop by unmasking pre-existing CXCR4-using virus or through selection of CCR5-tropic resistant virus, characterized by plat...
Сохранить в:
| Опубликовано в: : | Antivir Chem Chemother |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6931239/ https://ncbi.nlm.nih.gov/pubmed/31856576 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040206619895706 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|